Mark Woodhead

Last updated

Professor Mark Andrew Woodhead FRCP FERS (born 21 December 1954) is a world authority on lung infection and pneumonia. [1] [2] [3] [4] He has been the National Clinical Adviser on pneumonia to the Department of Health since 2010, [1] [5] a Consultant in General and Respiratory Medicine at the Manchester Royal Infirmary since 1992, Honorary Clinical Professor of Respiratory Medicine at the University of Manchester since 2011 [1] and an Honorary Research Fellow of the Liverpool School of Tropical Medicine since 2013. [6]

Contents

Early life

Mark Andrew Woodhead was born on 21 December 1954. [7] He was educated at Bedford Modern School and King's College London where he graduated with first class honours in 1976 and was made MBBS in 1979. [8] He was made DM at the University of Nottingham in 1988. [8]

Career

Woodhead started his career as House Officer at King's College Hospital in 1979 before spending five months at the Queen Elizabeth Hospital, King's Lynn. [8] He was Senior House Officer at the Nottingham City Hospital and Nottingham General Hospital between 1980 and 1982 before his appointment as Registrar in Medicine at the Nottingham University Hospitals. [8] He was made Senior Registrar of St George's Hospital and the Royal Brompton Hospital in 1987 [8] until his appointment as a Consultant in General and Respiratory Medicine at the Manchester Royal Infirmary in 1992. [1]

Woodhead is a world authority on lung infection and pneumonia. [1] He is a member of the British Thoracic Society, a Fellow of the European Respiratory Society, [2] a member of the American Thoracic Society, [8] Chairman of the European Respiratory Society’s Lower Respiratory Infection Guidelines Group and a section editor of the European Respiratory Journal. [1] [9] He is also a member (and Chairman of the Public Education subcommittee) of the Department of Health Specialist Advisory Committee on Antimicrobial Resistance, [1] [10] a member of the British Thoracic Society Pneumonia Guidelines Committee and editor of the international textbook Respiratory Infections. [1] [11]

Woodhead was made MRCP in 1982 and FRCP in 1996. [8] He was made Honorary Clinical Professor of Respiratory Medicine at the University of Manchester in 2011 [1] and Honorary Research Fellow of the Liverpool School of Tropical Medicine in 2013. [6]

Selected work

Related Research Articles

<span class="mw-page-title-main">Pneumonia</span> Inflammation of the alveoli of the lungs

Pneumonia is an inflammatory condition of the lung primarily affecting the small air sacs known as alveoli. Symptoms typically include some combination of productive or dry cough, chest pain, fever, and difficulty breathing. The severity of the condition is variable.

<span class="mw-page-title-main">Bronchiectasis</span> Disease of the lungs

Bronchiectasis is a disease in which there is permanent enlargement of parts of the airways of the lung. Symptoms typically include a chronic cough with mucus production. Other symptoms include shortness of breath, coughing up blood, and chest pain. Wheezing and nail clubbing may also occur. Those with the disease often get lung infections.

<span class="mw-page-title-main">Pleural empyema</span> Medical condition

Pleural empyema is a collection of pus in the pleural cavity caused by microorganisms, usually bacteria. Often it happens in the context of a pneumonia, injury, or chest surgery. It is one of the various kinds of pleural effusion. There are three stages: exudative, when there is an increase in pleural fluid with or without the presence of pus; fibrinopurulent, when fibrous septa form localized pus pockets; and the final organizing stage, when there is scarring of the pleura membranes with possible inability of the lung to expand. Simple pleural effusions occur in up to 40% of bacterial pneumonias. They are usually small and resolve with appropriate antibiotic therapy. If however an empyema develops additional intervention is required.

<span class="mw-page-title-main">Oseltamivir</span> Antiviral medication used against influenza A and influenza B

Oseltamivir, sold under the brand name Tamiflu, is an antiviral medication used to treat and prevent influenza A and influenza B, viruses that cause the flu. Many medical organizations recommend it in people who have complications or are at high risk of complications within 48 hours of first symptoms of infection. They recommend it to prevent infection in those at high risk, but not the general population. The Centers for Disease Control and Prevention (CDC) recommends that clinicians use their discretion to treat those at lower risk who present within 48 hours of first symptoms of infection. It is taken by mouth, either as a pill or liquid.

<span class="mw-page-title-main">Lower respiratory tract infection</span> Medical term

Lower respiratory tract infection (LRTI) is a term often used as a synonym for pneumonia but can also be applied to other types of infection including lung abscess and acute bronchitis. Symptoms include shortness of breath, weakness, fever, coughing and fatigue. A routine chest X-ray is not always necessary for people who have symptoms of a lower respiratory tract infection.

The pneumonia severity index (PSI) or PORT Score is a clinical prediction rule that medical practitioners can use to calculate the probability of morbidity and mortality among patients with community acquired pneumonia.

Community-acquired pneumonia (CAP) refers to pneumonia contracted by a person outside of the healthcare system. In contrast, hospital-acquired pneumonia (HAP) is seen in patients who have recently visited a hospital or who live in long-term care facilities. CAP is common, affecting people of all ages, and its symptoms occur as a result of oxygen-absorbing areas of the lung (alveoli) filling with fluid. This inhibits lung function, causing dyspnea, fever, chest pains and cough.

Ventilator-associated pneumonia (VAP) is a type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals. As such, VAP typically affects critically ill persons that are in an intensive care unit (ICU) and have been on a mechanical ventilator for at least 48 hours. VAP is a major source of increased illness and death. Persons with VAP have increased lengths of ICU hospitalization and have up to a 20–30% death rate. The diagnosis of VAP varies among hospitals and providers but usually requires a new infiltrate on chest x-ray plus two or more other factors. These factors include temperatures of >38 °C or <36 °C, a white blood cell count of >12 × 109/ml, purulent secretions from the airways in the lung, and/or reduction in gas exchange.

Bronchoalveolar lavage (BAL), also known as bronchoalveolar washing, is a diagnostic method of the lower respiratory system in which a bronchoscope is passed through the mouth or nose into an appropriate airway in the lungs, with a measured amount of fluid introduced and then collected for examination. This method is typically performed to diagnose pathogenic infections of the lower respiratory airways, though it also has been shown to have utility in diagnosing interstitial lung disease. Bronchoalveolar lavage can be a more sensitive method of detection than nasal swabs in respiratory molecular diagnostics, as has been the case with SARS-CoV-2 where bronchoalveolar lavage samples detect copies of viral RNA after negative nasal swab testing.

CURB-65, also known as the CURB criteria, is a clinical prediction rule that has been validated for predicting mortality in community-acquired pneumonia and infection of any site. The CURB-65 is based on the earlier CURB score and is recommended by the British Thoracic Society for the assessment of severity of pneumonia. It was developed in 2002 at the University of Nottingham by Dr. W.S. Lim et al. In 2018 a new toolkit was presented on the basis of CURB-65.

<span class="mw-page-title-main">Hospital-acquired pneumonia</span> Pneumonia contracted by a hospital patient

Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus.

<span class="mw-page-title-main">Peter Barnes (respiratory scientist)</span> British pulmonary scientist and clinician

Sir Peter John Barnes, FRCP, FCCP, FMedSci, FRS is a British respiratory scientist and clinician, a specialist in the mechanisms and treatment of asthma and chronic obstructive pulmonary disease (COPD). He was Margaret Turner-Warwick Professor of Thoracic Medicine at the National Heart & Lung Institute, previous head of respiratory medicine at Imperial College and honorary consultant physician at the Royal Brompton Hospital London. He is one of the most highly cited scientists in the world

<span class="mw-page-title-main">Zhong Nanshan</span> Chinese pulmonologist

Zhong Nanshan is a Chinese pulmonologist. He was president of the Chinese Medical Association from 2005 to 2009 and is currently the editor-in-chief of the Journal of Thoracic Disease. He is a recipient of Medal of the Republic, the highest honour of China.

<span class="mw-page-title-main">Sam Ahmedzai</span> British care specialist

Professor Emeritus Sam H Ahmedzai FRCP, FRCPGlas, FFPMRCoA is a British supportive and palliative care specialist and an Honorary Consultant Physician in Palliative Medicine.

Sir Geoffrey Marshall (1887–1982) was an English physician, pulmonologist, and pioneer of anaesthia.

Professor Richard M. Leach FRCP is a British Consultant Physician and Professor at Guy's and St Thomas’ NHS Foundation Trust, who is accredited in general, respiratory and critical care medicine. He has pioneered multiple respiratory care techniques and been instrumental in the development of numerous NICE guidelines relating to acute medicine. It has been reported that he led the care of British prime minister Boris Johnson during the 2020 COVID-19 pandemic.

Francesco Blasi is an Italian Medical scientist and professor. His domain of research is respiratory medicine. He has been the president of European Respiratory Society (ERS) during 2012–13. He has served as the president of Italian Respiratory Society during 2015–17. He is presently serving as one of the board of directors of University of Milan and is the professor of respiratory medicine in department pathophysiology and transplantation in University of Milan.

Wei Shen Lim, KBE, is a consultant respiratory physician and honorary professor of medicine at Nottingham University Hospitals NHS Trust, England.

<span class="mw-page-title-main">Ian Town</span> Chief Science Advisor to Ministry of Health, NZ

George Ian TownFRACP is a New Zealand respiratory scientist and health official. He was appointed the Chief Science Advisor to the New Zealand Ministry of Health in 2019.

Jadwiga “Wisia” A. Wedzicha is a British physician and Professor of Respiratory Medicine at the National Heart and Lung Institute. Her research has considered the causes and impact of chronic obstructive pulmonary disease. She was elected as Fellow of the UK Academy of Medical Sciences in 2013 and awarded the Helmholtz International Fellow Award.

References

  1. 1 2 3 4 5 6 7 8 9 Central Manchester University Hospitals Website
  2. 1 2 Administrator. "All Fellowships – Fellow of ERS (FERS) -". ersnet.org. Retrieved 19 July 2015.
  3. ↑ Sehgal, N.; Woodhead, M. (2011). "Predicting the unpredictable: Is it possible clinically to separate H1N1 from non-H1N1 community-acquired pneumonia?". Thorax. 66 (3): 187–188. doi: 10.1136/thx.2010.157404 . PMID   21335459.
  4. ↑ Schünemann, Holger J.; Woodhead, Mark; Anzueto, Antonio; Buist, Sonia; MacNee, William; Rabe, Klaus F.; Heffner, John (2009). "A vision statement on guideline development for respiratory disease: The example of COPD". The Lancet. 373 (9665): 774–779. doi:10.1016/S0140-6736(08)61347-1. PMID   18835641. S2CID   31942725.
  5. ↑ "NICE – Server error". nice.org.uk. Retrieved 19 July 2015.
  6. 1 2 "Honorary appointment for Professor Mark Woodhead". lstmed.ac.uk. Archived from the original on 22 July 2015. Retrieved 19 July 2015.
  7. ↑ "Genealogy, Family Trees & Family History Records at Ancestry.co.uk". ancestry.co.uk. Retrieved 19 July 2015.
  8. 1 2 3 4 5 6 7 "Turkish Thoracic Society 16th Annual Congress". toraks.org.tr. Retrieved 19 July 2015.
  9. ↑ "ERJ – European Respiratory Journal Editorial Board". ersjournals.com. Archived from the original on 7 June 2015. Retrieved 19 July 2015.
  10. ↑ Woodhead, Mark; Fleming, Douglas; Wise, Richard (2004). "Antibiotics, resistance, and clinical outcomes". BMJ. 328 (7451): 1270–1271. doi:10.1136/bmj.328.7451.1270. PMC   420154 . PMID   15166040.
  11. ↑ Mandell, Lionel; Woodhead, Mark; Ewig, Santiago; Torres, Antoni (27 October 2006). Respiratory Infections. ISBN   9780340816943 . Retrieved 19 July 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.